Compare BOLD & CLPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOLD | CLPR |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | 161 |
| Industry | | Real Estate Investment Trusts |
| Sector | | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.5M | 46.4M |
| IPO Year | 2024 | 2015 |
| Metric | BOLD | CLPR |
|---|---|---|
| Price | $2.51 | $2.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 2.3M | 161.5K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 10.73% |
| EPS Growth | ★ 32.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $109,997,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.82 |
| 52 Week Low | $0.96 | $2.69 |
| 52 Week High | $2.79 | $4.61 |
| Indicator | BOLD | CLPR |
|---|---|---|
| Relative Strength Index (RSI) | 76.94 | 42.14 |
| Support Level | $1.08 | N/A |
| Resistance Level | $2.79 | $3.28 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 79.21 | 28.61 |
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.